Participating Companies

Aardvark Therapeutics
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of small molecule ther­a­peu­tics that ac­ti­vate in­nate home­o­stat­ic path­ways for the treat­ment of dis­ease. Lead prod­uct, ARD-101, is a first-in-class oral com­po­si­tion that is gut re­strict­ed, yet con­veys sys­temic ef­fects via ac­ti­va­tion of gut pep­tide hor­mone se­cre­tion. Pre­clin­i­cal da­ta de­mon­s­trate safe­ty as well as ef­fi­ca­cy in a num­ber of metabolic and in­flam­ma­to­ry dis­ease mod­els. [more in­for­ma­tion]
Adiso Therapeutics inc
AD­S024 (SS-LBP) has just com­plet­ed a Phase 1b study for the pre­ven­tion of re­cur­rent CDI and will be un­der­tak­ing a Phase 2 study in mod­er­ate ul­cer­a­tive coli­tis (UC) this year. AD­S051 is near­ly com­plet­ing en­roll­ment in a Ph1b study in mod­er­ate-to-se­vere ul­cer­a­tive coli­tis (UC). Adi­so is al­so de­vel­op­ing a nov­el du­al in­flam­ma­some in­hibi­tor (NL­R­P3 & NL­R­P1) in dis­cov­ery phase which is be­ing ini­tial­ly ex­plored in re­s­pi­ra­to­ry in­flam­ma­tion, and der­mal ap­pli­ca­tion with mul­ti­ple fu­ture ther­a­peu­tic ar­eas to pur­sue. [more in­for­ma­tion]
Affibody
Lead can­di­date Izok­ibep, sup­port­ed by part­n­er­ship with Ace­lyrin, is an IL-17 in­hibi­tor with mul­ti­ple Ph2 pro­grams in progress (PSO, axS­pA, uvei­tis, HS, PsA). ACR50 pri­mary end­point met for 16 wk da­ta in PsA. First pa­tient dosed in piv­o­tal Phase 2b trial for uvei­tis filed in 1H2022 with 24 wk da­ta ex­pect­ed in 2023. [more in­for­ma­tion]
AgomAb Therapeutics
Cap­i­tal­iz­ing on a deep un­der­s­tand­ing of growth fac­tor bi­ol­o­gy, Agomab has built a pipe­line of prod­uct can­di­dates that ad­dress well-vali­dat­ed and po­ten­tial­ly dis­ease-mod­i­fy­ing tar­gets: Trans­form­ing Growth Fac­tor Be­ta (TGF-&be­ta;) through in­hi­bi­tion of its in­tra­cel­lu­lar re­cep­tor ALK-5 and He­p­a­to­cyte Growth Fac­tor (HGF) through ag­on­ism of its re­cep­tor MET. The com­pany’s lead drug can­di­date, AGMB-129, is a gas­troin­testi­nal tract-re­strict­ed oral ALK-5 in­hibi­tor in de­vel­op­ment for the treat­ment of fi­brostenot­ic Crohn’s dis­ease and is cur­rent­ly in fi­nal stages of a Phase 1 clin­i­cal trial. The se­cond TGF-&be­ta; tar­get­ing drug can­di­date, AGMB-447, is a lung-re­strict­ed ALK-5-in­hibi­tor in de­vel­op­ment for the treat­ment of idio­path­ic pul­mo­nary fi­bro­sis and is cur­rent­ly in IND-en­abling studies. [more in­for­ma­tion]
Alladapt
De­vel­op­ing a po­ten­tial­ly best-in-class oral im­munother­a­py that ad­dress­es a broad range of food al­ler­gies. AD­P101, which is in a Ph 1/2 study and an OLE study, is de­signed to de­sen­si­tize pa­tients al­ler­g­ic to one or to mul­ti­ple foods si­mul­ta­ne­ous­ly to miti­gate the risk of se­vere, life-threat­en­ing al­ler­g­ic re­ac­tions. The Com­pany was co-found­ed by Dr. Kari Nadeau, a renowned food al­ler­gist, and former 23andMe ex­ec, Ash­ley Dom­bkows­ki who serves is CEO. Da­ta from Ph 1/2 study ex­pect­ed 1Q23. [more in­for­ma­tion]
Arbor Biotechnologies
With the most ex­ten­sive li­brary of CRIS­PR nu­cleas­es in the in­dus­try, a deep bench of world-class foun­ders, sci­en­tif­ic ad­vi­sors, and a lead­er­ship team with a proven track re­cord of de­vel­op­ing nov­el plat­forms and ther­a­peu­tics, Ar­bor is well-po­si­tioned to de­vel­op cu­ra­tive ge­net­ic medicines for all pa­tients with ge­net­ic dis­eas­es. Ar­bor’s pipe­line is pow­ered by its pro­pri­e­tary biodis­cov­ery en­gine, which blends com­pu­ta­tio­n­al search and sci­en­tif­ic ex­per­tise to dis­cov­er, screen, and en­gi­neer pro­teins at un­prece­dent­ed scale and speed. Ar­bor has raised more than $300 mil­lion to date and top in­ves­tors in­clude ARCH Ven­ture Part­n­ers, Te­masek, Al­ly Bridge Group, and TCG Crossover. [more in­for­ma­tion]
Bexion Pharmaceuticals
A clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a new gen­er­a­tion of bi­o­log­ic im­munother­a­py to treat Solid Tu­mor Can­cers and Che­mother­a­py In­duced Pe­ripher­al Neu­ro­pa­thy (CIPN). Bexion's lead as­set BXQ-350 ac­ti­vates Sphin­goloid Metabolism and has de­mon­s­trat­ed ex­cel­lent safe­ty and monother­a­py ben­e­fits across mul­ti­ple tu­mor types in its com­plet­ed adult and pe­di­a­tric Ph 1 study. Ph 2 study in CRC ex­pect­ed 4Q22. The Com­pany has $80M raised to date. [more in­for­ma­tion]
BrickBio
Brick­Bio is ac­tive­ly de­vel­op­ing two lead in­ter­nal can­di­dates with on­col­o­gy in­di­ca­tions, while co-de­vel­op­ing two can­di­dates with large phar­ma part­n­ers, on which Brick­Bio owns 50% of the in­tel­lec­tu­al prop­er­ty of the re­sult­ing drug. [more in­for­ma­tion]
Caraway Therapeutics
The Com­pany is backed by top-ti­er in­ves­tors, in­clud­ing SV Health In­ves­tors, Ab­b­Vie Ven­tures, MR­LV Fund, Am­gen Ven­tures, De­men­tia Dis­cov­ery Fund, Alexan­dria Ven­ture In­vest­ments, and Ei­sai In­no­va­tion. [more in­for­ma­tion]
Catamaran Bio
Our pro­pri­e­tary ca­pa­bil­i­ties en­able us to har­ness the na­t­u­ral can­cer-fight­ing prop­er­ties of NK cells and en­hance and tailor their ef­fec­tive­ness with the pow­er of syn­thet­ic bi­ol­o­gy and in­no­va­tive non-vi­ral cell en­gi­neer­ing. We are us­ing our TAIL­WIND™ plat­form, an in­te­grat­ed suite of tech­nolo­gies, to spe­cif­i­cal­ly ad­dress the end-to-end meth­ods of en­gi­neer­ing, pro­cess­ing and man­u­fac­tur­ing NK cells and rapid­ly ad­vance our pipe­line of CAR-NK cell ther­a­py pro­grams. Our team com­bines ex­pe­ri­enced bio­phar­ma­ceu­ti­cal lead­er­ship with found­ing sci­en­tists who are pi­oneers in NK cell bi­ol­o­gy, en­gi­neer­ing, man­u­fac­tur­ing, and clin­i­cal ap­pli­ca­tion. [more in­for­ma­tion]
Celsius Therapeutics
Cel­sius Ther­a­peu­tics is a biotech­nol­o­gy com­pany that de­vel­ops pre­ci­sion medicines for can­cer and au­toim­mune dis­ease pa­tients. [more in­for­ma­tion]
Cerevance
De­vel­op­er of nov­el ther­a­peu­tics in­tend­ed to ad­vance new medicines for se­ri­ous neu­ro­log­i­cal dis­eas­es. [more in­for­ma­tion]
CoRegen Inc
This ther­a­py is ef­fec­tive with com­plete and durable elim­i­na­tion of can­cer cells, safe with no signs of toxic­i­ty, no in­flam­ma­tion, re­tain­ing healthy metabolism, and pre­ven­tive of can­cer re­cur­rence. [more in­for­ma­tion]
DTx Pharma
The com­pany's tech­nol­o­gy en­ables ef­fi­cient de­liv­ery of nu­cle­ic acid drugs to tis­sues through­out the body, en­abling health­care providers to de­liv­er oli­gos in vi­vo at ther­a­peu­ti­cal­ly rel­e­vant dos­es that work in many cell types in­clud­ing neu­rons, en­dothe­lial and T cells. Their pipe­line con­sists of nov­el ther­a­peu­tic can­di­dates to help pa­tients with neu­ro­mus­cu­lar, mus­cle, and CNS dis­eas­es. DTx has raised more than $100M in com­bined in­vest­ment from health­care in­ves­tors in­clud­ing RA Cap­i­tal and Ac­cess Biotech­nol­o­gy, phar­ma­ceu­ti­cal com­pa­nies such as Eli Lil­ly, the Na­tio­n­al In­sti­tute of Health (NIH), and re­search foun­da­tions such as the CMT Re­search Foun­da­tion (CMTRF). [more in­for­ma­tion]
Enterome
Rec­og­niz­ing that the Phar­ma in­dus­try is on­ly be­gin­n­ing to un­der­s­tand how to po­ten­tial­ly op­ti­mize the ther­a­peu­tic ben­e­fits of T cell ther­a­pies (CART & TCRT) and with a great deal still to learn, En­terome is tak­ing a de­lib­er­ate­ly new and dif­fer­ent ap­proach with its tech­nol­o­gy plat­form en­abling each pa­tient to ben­e­fit from a spe­cif­ic and ma­jor ex­pan­sion of the best part of its own T cell reper­toire (Ef­fec­tor Me­m­o­ry T cells), in a high­ly so­phis­ti­cat­ed and un­prece­dent­ed way. Our On­coMim­icTM tech­nol­o­gy is en­abling the over­com­ing of im­mune tol­er­ance against can­cer cells with broad ap­pli­ca­bil­i­ty in the high un­met need solid tu­mor space via an off-the-shelf, easy to man­u­fac­ture tech­nol­o­gy. Our lead as­set EO2401 is cur­rent­ly in phase 2 in re­cur­rent Glioblas­to­ma (rGBM) and piv­o­tal trial in Adre­nal car­ci­no­ma (ACC). [more in­for­ma­tion]
Epic Bio
Epi­cris­pr Biotech­nolo­gies is a pre-clin­i­cal stage gene ther­a­py com­pany build­ing the world’s most ex­pan­sive ther­a­peu­tic pipe­line based on the emerg­ing sci­ence of epi­ge­net­ic en­gi­neer­ing. Led by CRIS­PR pi­oneer Lei Stan­ley Qi, PhD, Epic has de­vel­oped the Gene Ex­pres­sion Mo­d­u­la­tion Sys­tem (GEMS) plat­form, de­signed to dial gene ex­pres­sion up or down with­out per­ma­nent­ly al­ter­ing the DNA, and us­es Cas12f to de­liv­er ge­net­ic ther­a­pies that act on the epigenome. The Com­pany's unique epi­ge­net­ic ap­proach pre­sents enor­mous ther­a­peu­tic po­ten­tial for count­less com­plex dis­eas­es. [more in­for­ma­tion]
Geneius
Geneius Biotech­nol­o­gy en­ables per­so­n­al­ized medicine to trans­form can­cer ther­a­py by tar­get­ing mul­ti­ple can­cer driv­er mu­ta­tions with T cells that spe­cif­i­cal­ly kill can­cer cells (not nor­mal cells) and mod­i­fy the tu­mor mi­croen­vi­ron­ment across mul­ti­ple solid and he­ma­to­log­ic can­cers re­sult­ing in a molec­u­lar rather than a tis­sue-based prod­uct la­bel for the ther­a­py of can­cer. The com­pany us­es a pro­pri­e­tary RNA tech­nol­o­gy that com­plete­ly rev­o­lu­tion­izes the pro­duc­tion of per­so­n­al­ized T cell prod­ucts and nov­el tran­sient tech­nolo­gies that re­mod­el the tu­mor mi­croen­vi­ron­ment. The com­pany has de­vel­oped T cell prod­ucts for first-line, out­pa­tient ther­a­py of can­cer by lo­cal com­mu­ni­ty on­col­o­gists via two 30-minute in­fu­sions with­out tox­ic che­mother­a­py, IL-2 or lym­phode­ple­tion. [more in­for­ma­tion]
hC Bioscience, Inc.
hC Bio­s­cience, Inc is an in­no­va­tor and pi­oneer of pro­tein edit­ing us­ing gene and con­text ag­nos­tic en­gi­neered tR­NA. The Com­pany's first in class ap­proach for pro­tein edit­ing ad­vances far be­yond genome edit­ing to the di­rect mod­i­fi­ca­tion of the pro­teome, lead­ing to more ac­cu­rate and ef­fi­cient gene ther­a­py treat­ment op­tions. [more in­for­ma­tion]
Imbria Pharmaceuticals
Im­bria Phar­ma­ceu­ti­cals, a biotech­nol­o­gy com­pany, de­vel­op­ing nov­el ther­a­pies de­signed to sub­s­tan­tial­ly im­prove the lives of pa­tients with life-al­ter­ing dis­eas­es, with lo­ca­tions in San Die­go, CA, and Bos­ton, MA [more in­for­ma­tion]
Immunai
De­vel­op­er of a tech­nol­o­gy in­tend­ed to pro­vide treat­ments for on­col­o­gy and au­to-im­mune di­s­or­ders. The com­pany's tech­nol­o­gy com­bines bi­ol­o­gy with ma­chine-learn­ing to un­rav­el the im­mune sys­tem, en­abling clini­cians to com­pre­hen­sive­ly view and in­ter­ro­gate da­ta and de­rive nov­el con­clu­sions on the un­der­ly­ing mech­anisms of dis­ease. [more in­for­ma­tion]
ImmuneSensor
A pri­vate, clin­i­cal stage ther­a­peu­tic in­nate im­mu­ni­ty com­pany de­vel­op­ing drugs tar­get­ing the cGAS-ST­ING path­way for the treat­ment of can­cer and au­toim­mune dis­eas­es. The com­pany was co-found­ed by Dr. Zhi­jian “James” Chen of UTSW who won the 2019 Break-through prize and 2018 Lurie prize for the dis­cov­ery of the cGAS-ST­ING path­way. The com­pany pipe­line in­cludes a clin­i­cal stage ST­ING ag­on­ist, cur­rent­ly in monother­a­py and ICI com­bi­na­tion trial, with ex­pec­ta­tions to en­ter Phase 2 in 2H23. [more in­for­ma­tion]
Imvax
Im­vax’s im­munother­a­py plat­form is a mul­ti-step pro­cess de­signed to de­liv­er per­so­n­al­ized, whole tu­mor-de­rived im­munother­a­pies. [more in­for­ma­tion]
Indapta Therapeutics
In­dap­ta Ther­a­peu­tics is a pri­vate­ly held biotech­nol­o­gy com­pany fo­cused on de­vel­op­ing and com­mer­cial­iz­ing a pro­pri­e­tary, off-the-shelf, al­lo­gene­ic FcR&gam­ma;-de­fi­cient na­t­u­ral killer (G-NK) cell ther­a­py to treat mul­ti­ple types of can­cers and ad­dress the lim­i­ta­tions of cur­rent­ly avai­l­able au­tol­o­gous T cell ther­a­pies. The Com­pany most re­cent­ly raised over $50 mil­lion in Se­ries A fi­nanc­ing and com­mit­ments co-led by RA Cap­i­tal Man. [more in­for­ma­tion]
iOnctura
iOnc­tu­ra’s drug de­vel­op­ment pro­grams com­bine im­mune-me­di­at­ed and di­rect an­ti-tu­mor ac­tiv­i­ty to de­liv­er molecules with su­pe­ri­or clin­i­cal ef­fi­ca­cy and safe­ty in on­col­o­gy. Its lead pro­gram, IOA-244, has de­liv­ered com­pelling clin­i­cal monother­a­py ef­fi­ca­cy and safe­ty da­ta in solid and he­ma­to­log­ic ma­lig­nan­cies and has syn­er­gis­tic po­ten­tial with stan­dard of care agents across tu­mor types. iOnc­tu­ra’s se­cond clin­i­cal pro­gram, IOA-289, is ini­ti­at­ing dos­ing in a Phase 1b in first-line pan­cre­at­ic can­cer in 3Q22. [more in­for­ma­tion]
KBio
Cre­at­ing the new gen­er­a­tion of bi­o­log­ics us­ing its plant-based plat­form that has de­mon­s­trat­ed an abil­i­ty to cre­ate po­ten­tial­ly bet­ter drug can­di­dates at a frac­tion of the time and cost of con­ven­tio­n­al plat­forms. Fo­cused on dis­cov­er­ing mon­o­clo­n­al anti­bodies tar­get­ing vali­dat­ed path­ways for rare and in­fec­tious dis­eas­es and, due to the speed and ac­cu­ra­cy of its anti­body pro­duc­tion sys­tem, is po­si­tioned well to de­vel­op fast fol­low­er ther­a­pies against vali­dat­ed drug tar­gets. [more in­for­ma­tion]
KisoJi Biotech Inc.
Ki­so­Ji is a lead­ing next-gen­er­a­tion anti­body com­pany de­vel­op­ing high­ly dif­fer­en­ti­at­ed ther­a­peu­tic anti­bodies with nov­el and/or mul­ti-spe­cif­ic func­tio­n­al­i­ty to ad­dress dif­fi­cult tar­gets in on­col­o­gy and other dis­eas­es. [more in­for­ma­tion]
LENZ [0910137D]
LENZ Ther­a­peu­tics is a late-stage clin­i­cal com­pany de­vel­op­ing in­no­va­tive oph­thalmic phar­ma­ceu­ti­cal prod­ucts that im­prove vi­sion. Their lead pro­gram is an ace­c­li­dine based eye drop de­signed to re­s­tore the loss of near vi­sion as­so­ci­at­ed with pres­by­opia. [more in­for­ma­tion]
MiNA Therapeutics
Lead­er in RNA ac­ti­va­tion (RNAa). Tech­nol­o­gy ca­pa­ble of drug­ging any pro­tein tar­get to in­crease na­t­u­ral pro­tein pro­duc­tion in pa­tients own cells. Im­muno-on­col­o­gy and rare dis­ease pipe­line with 10 clin­i­cal as­sets ex­pect­ed by 2025 and first FDA ap­pro­val in 2024. Key pro­grams in­clude MTL-CEP­BA (on­go­ing ran­domized Ph2 in 2L HCC, Ph1/1b in ad­vanced solid tu­mors re­sis­tant to an­ti-PD1), MTL-ST­ING, mono­gene­ic rare dis­ease pro­grams. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Minerva Biotechnologies
A clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing can­cer im­munother­a­pies and drugs to tar­get 75% of solid tu­mors and to pre­vent can­cer me­tas­ta­sis. Min­er­va has a pipe­line that in­cludes next-gen CAR Ts and other mo­dal­i­ties. The Com­pany has an on­go­ing Phase I/II study of huM­NC2-CAR44, an au­tol­o­gous CAR T ther­a­py, tar­get­ing the tu­mor-as­so­ci­at­ed form of MUC1 (MUC1*) which is a growth fac­tor re­cep­tor that drives growth of an es­ti­mat­ed 93% of breast can­cers. [more in­for­ma­tion]
MISSION Therapeutics
Mis­sion Ther­a­peu­tics is de­vel­op­ing a rich pipe­line of first-in-class small molecule DUB in­hibi­tors for a num­ber of sig­ni­f­i­cant clin­i­cal in­di­ca­tions. [more in­for­ma­tion]
Model Medicines
Mod­el Medicines is a new type of soft­ware com­pany, com­bin­ing hu­man ex­per­tise and ma­chine learn­ing to ac­cel­er­ate the cre­a­tion of life-chang­ing Phase II/III ready drug can­di­dates in days rather than de­cades. [more in­for­ma­tion]
NodThera Limited
Op­er­a­tor of a clin­i­cal-stage biotech­nol­o­gy com­pany in­tend­ed to de­vel­op medicines to treat dis­eas­es driv­en by chron­ic in­flam­ma­tion. The com­pany is fo­cused on de­vel­op­ing a new class of po­tent and se­lec­tive NL­R­P3 in­flam­ma­some in­hibi­tors, pro­vid­ing med­i­cal prac­ti­tion­ers with tools to help pa­tients with vari­ous chron­ic dis­eas­es. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Phase 2b ICO­NA NASH trial icos­abu­tate showed sig­ni­f­i­cant de­creas­es in NASH and fi­brot­ic bio­mark­ers and is sche­d­uled to read­out biop­sy da­ta in 1Q23. Two ad­di­tio­n­al SE­FAs (1024 and 6179) in Phase 1 clin­i­cal trials for pa­tients with dys­lipi­demia and the or­phan in­di­ca­tion IFALD, re­spec­tive­ly. [more in­for­ma­tion]
Oligon
Oli­gon Inc. is an emerg­ing biotech­nol­o­gy com­pany de­vel­op­ing a nov­el class of mul­ti­mo­dal RNA ther­a­peu­tics for the treat­ment of can­cer & other com­plex multi­genic dis­eas­es. heir pro­pri­e­tary SeekR™ plat­form is used to dig­i­tal­ly en­gi­neer and rapid­ly pro­duce self-de­liv­er­ing ther­a­peu­tics which tar­get spe­cif­ic tis­sues with un­prece­dent­ed pre­ci­sion and ac­cu­ra­cy. [more in­for­ma­tion]
Pipeline Therapeutics
Its flag­ship pro­gram, PIPE-307, has com­plet­ed a Phase 1 clin­i­cal trial in healthy vol­un­teers and will ad­vance in­to a Phase 2 clin­i­cal study in re­laps­ing-re­mitt­ing MS pa­tients. [more in­for­ma­tion]
Plexium
Plex­i­um is the pre­mi­er, next-gen­er­a­tion Tar­get­ed Pro­tein Degra­da­tion (TPD) com­pany seek­ing to dis­cov­er a wide range of mono­va­lent tar­get pro­tein de­graders that ad­dress the lim­i­ta­tions of heter­ob­i­func­tio­n­al de­graders and cere­blon IMiDs. The com­pany is pow­ered by its pro­pri­e­tary drug dis­cov­ery plat­form de­signed to iden­ti­fy nov­el small molecules that in­duce se­lec­tive degra­da­tion of drug tar­get pro­teins through E3 li­g­ase me­di­at­ed pro­tea­so­mal degra­da­tion. From molec­u­lar glues to mono­va­lent de­graders, Plex­i­um is ad­vanc­ing a pipe­line of nov­el tar­get­ed pro­tein de­graders for the treat­ment of can­cer, neu­rode­gen­er­a­tion, and other dis­eas­es. [more in­for­ma­tion]
Prilenia
Prile­nia is a clin­i­cal stage biotech com­pany, led by Michael Hay­den, MD, PhD., to­gether with a high­ly ex­pe­ri­enced team with a track re­cord of suc­cess. Michael is a world-renowned sci­en­tist in Hunt­ing­ton Dis­ease re­search. He is the former Presi­dent of Glob­al R&D and Chief Sci­en­tif­ic Of­fi­cer at Te­va Phar­ma­ceu­ti­cals, where he led the de­vel­op­ment of ~35 new prod­ucts to­wards ap­pro­val in sev­er­al ma­jor mar­kets, pre­dom­i­nant­ly in CNS. The com­pany has re­cent­ly raised $68.5M in a Se­ries A fi­nanc­ing round to launch [more in­for­ma­tion]
Prolacta Bioscience
Pro­lac­ta Bio­s­cience pro­vides hu­man milk-based nu­tri­tio­n­al prod­ucts for pre­ma­ture in­fants in the neo­na­tal in­ten­sive care unit (NICU). They are the world’s lead­ing hos­pi­tal provider of 100% hu­man milk–based nu­tri­tio­n­al prod­ucts, made from 100% donor milk in­stead of cow milk. [more in­for­ma­tion]
SparingVision
Th­ese nov­el medicines could form the ba­sis of a suite of new sight-sav­ing treat­ments with po­ten­tial ap­pli­ca­tions across many other reti­nal dis­eas­es, re­gard­less of ge­net­ic cause. The Com­pany is sup­port­ed by a strong, in­ter­na­tio­n­al­ly renowned team who aim to har­ness the po­ten­tial of ge­nom­ic medicine to de­liv­er new treat­ments to all oc­u­lar dis­ease pa­tients as quick­ly as pos­si­ble. Spar­ingVi­sion has raised &eu­ro;60 mil­lion to date and its in­ves­tors in­clude 4BIO Cap­i­tal, Ad­vent France Biotech­nol­o­gy, Bpifrance, Foun­da­tion Fight­ing Blind­ness (US), Fon­da­tion Voir & En­ten­dre, UPMC En­ter­pris­es, Jei­to Cap­i­tal and Ysios Cap­i­tal. [more in­for­ma­tion]
Transition Bio
Tran­si­tion Bio is a mi­crofluidics-driv­en drug dis­cov­ery plat­form com­pany work­ing to estab­lish a one-of-a-kind tech­nol­o­gy plat­form us­ing cell imag­ing and ma­chine learn­ing to rev­o­lu­tion­ize con­den­sate drug dis­cov­ery. [more in­for­ma­tion]
Treos Bio
De­vel­ops pre­ci­sion pep­tide can­cer im­munother­a­pies us­ing pa­tient HLA tar­get recog­ni­tion ge­net­ics based on pro­pri­e­tary com­pu­ta­tio­n­al da­ta sci­ence. Tre­os’ lead can­di­date is Po­lyPEPI-1018, an off-the-shelf im­munother­a­py for the treat­ment of me­tastat­ic col­orec­tal can­cer cur­rent­ly in a bio­mark­er-based Phase 1b clin­i­cal trial. Tre­os has raised $42 mil­lion to date. [more in­for­ma­tion]
Tune Therapeutics
Tune Ther­a­peu­tics, Inc. is uti­l­iz­ing the epigenome to treat com­plex, per­va­sive dis­eas­es that have long elud­ed treat­ment. With its ver­satile and pow­er­ful TEM­PO epige­nom­ic con­trol plat­form, Tune’s ex­pe­ri­enced team is pi­oneer­ing a new ther­a­peu­tic mo­dal­i­ty that can fine-tune any gene net­work with­out break­ing or per­ma­nent­ly rewrit­ing DNA. [more in­for­ma­tion]
XyloCor Therapeutics
Xy­lo­Cor Ther­a­peu­tics is a bio-phar­ma­ceu­ti­cal com­pany de­vel­op­ing gene ther­a­py for peo­ple with ad­vanced coro­nary artery dis­ease. It's lead drug can­di­date, XC001, is cur­rent­ly in Phase 2 with re­sults re­port­ing out in 2022 and 2023. Promis­ing Phase 1 re­sults were pre­sent­ed ear­li­er this year. [more in­for­ma­tion]